| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UL83 |
| Uniprot No | P06725 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 351-480aa |
| 氨基酸序列 | FDIDLLLQRGPQYSEHPTFTSQYRIQGKLEYRHTWDRHDEGAAQGDDDVWTSGSDSDEELVTTERKTPRVTGGGAMAGASTSAGRKRKSASSATACTSGVMTRGRLKAESTVAPEEDTDEDSDNEIHNPA |
| 预测分子量 | 18.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UL83重组蛋白的3篇虚构参考文献示例(实际文献需通过学术数据库检索获取)：
1. **《重组人巨细胞病毒UL83蛋白的表达及免疫原性分析》**
- 作者：张伟等
- 摘要：研究利用大肠杆菌系统成功表达UL83重组蛋白，并通过动物实验证实其可诱导特异性抗体产生，为HCMV疫苗研发提供基础数据。
2. **《Structural characterization of UL83/pp65 recombinant protein in cytomegalovirus》**
- 作者：Johnson A. et al.
- 摘要：通过X射线晶体学解析UL83重组蛋白的晶体结构，揭示其与宿主细胞蛋白相互作用的潜在位点，为抗病毒药物设计提供结构依据。
3. **《Recombinant UL83 protein-based ELISA for serodiagnosis of cytomegalovirus infections》**
- 作者：Chen L. et al.
- 摘要：开发基于重组UL83蛋白的ELISA检测方法，临床样本验证显示其灵敏度显著高于传统方法，适用于早期HCMV感染筛查。
注：以上为模拟内容，实际文献请通过PubMed、Google Scholar等平台以“UL83 recombinant protein”或“pp65 recombinant”为关键词检索。
**Background of UL83 Recombinant Protein**
UL83. also known as pp65. is a structural phosphoprotein encoded by the human cytomegalovirus (HCMV), a betaherpesvirus with significant clinical implications in immunocompromised individuals and neonates. The UL83 gene product, pp65. is a major tegument protein constituting up to 95% of the virion's protein content. It plays multifaceted roles in viral replication, immune evasion, and modulation of host cell processes. Notably, pp65 interacts with host immune components, such as inhibiting antigen presentation by major histocompatibility complex (MHC) class I molecules, thereby aiding viral persistence.
Recombinant UL83 protein is produced via molecular cloning techniques, typically expressed in bacterial (e.g., *E. coli*) or eukaryotic systems to retain post-translational modifications. Its production enables detailed study of HCMV pathogenesis, including mechanisms of immune evasion and latency. Additionally, recombinant pp65 serves as a critical tool in diagnostics, such as in ELISA-based assays to detect HCMV-specific antibodies, and in vaccine development due to its immunodominant T-cell epitopes. Studies also explore its potential as a target for antiviral therapies or adoptive T-cell immunotherapy.
Research on UL83 recombinant protein has advanced understanding of HCMV-host interactions, particularly in vulnerable populations like transplant recipients or HIV patients. Despite progress, challenges remain in addressing viral resistance and optimizing therapeutic applications. Overall, UL83 remains a focal point in virology for both basic research and translational medicine.
×
